Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02253537 · ClinicalTrials.gov registry record
Evaluation of the QuantiFERON-TB Test.
A clinical trial, sponsored by QIAGEN Gaithersburg.
- Completed
- Registry status
- 15
- Enrollment target
NCT02253537: Completed study, sponsored by QIAGEN Gaithersburg.
NCT02253537 is a clinical trial that has completed, run by QIAGEN Gaithersburg. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02253537 has completed, sponsored by QIAGEN Gaithersburg.
- COMPLETED
- Registry status
- 15 participants
- Enrollment target
Study Summary
To compare the results of the investigational test to the currently approved QuantiFERON-TB Gold In-Tube test.
Primary Outcome
Subjects who have clinical signs/symptoms indicating TB and who are receiving or have to start the treatment for active TB were tested. Subjects who were presenting with symptoms suggestive of TB disease and who have a positive acid-fast bacillus (AFB) smear or have Mycobacterium tuberculosis (MTB) in a specimen detected by nucleic acid amplification (NAA) or MTB complex Polymerase Chain Reaction (PCR), and who have received treatment for no more than 14 days upon enrollment.
Interventions
- DEVICE CST001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-02-02 |
| Est. Completion | 2016-04-26 |
What the finished NCT02253537 record still lists
NCT02253537 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 15 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which CST001 is the first listed.
NCT02253537 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02253537 about?
NCT02253537 is a clinical study titled "Evaluation of the QuantiFERON-TB Test.". To compare the results of the investigational test to the currently approved QuantiFERON-TB Gold In-Tube test.
What is the current status of trial NCT02253537?
This trial is currently completed. The enrollment target is 15 participants. The study started on 2015-02-02. Estimated completion is 2016-04-26.
What interventions are being tested in trial NCT02253537?
The interventions under investigation include: CST001 (DEVICE).
Who is sponsoring clinical trial NCT02253537?
This trial is sponsored by QIAGEN Gaithersburg, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI